We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+5.67%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.78B
AUM Growth
–
Cap. Flow
+$4.65B
Cap. Flow
% of AUM
97.21%
Top 10 Holdings %
Top 10 Hldgs %
14.27%
Holding
616
New
605
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$91.9M |
| 2 |
CELG
Celgene Corp
CELG
|
+$79.7M |
| 3 |
Apple
AAPL
|
+$78.2M |
| 4 |
Qualcomm
QCOM
|
+$73.5M |
| 5 |
Amgen
AMGN
|
+$71.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.38% |
| 2 | Financials | 14.02% |
| 3 | Technology | 12.7% |
| 4 | Industrials | 8.01% |
| 5 | Energy | 6.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTRA
226
DELISTED
Coterra Energy
CTRA
| $5.03M | 0.11% |
+169,692
| New | +$5.34M |
|
227
MetLife
MET
$61B
| $5.02M | 0.1% |
+104,070
| New | +$4.94M |
|
|
SIAL
228
DELISTED
SIGMA - ALDRICH CORP
SIAL
| $5M | 0.1% |
+36,403
| New | +$4.95M |
|
229
Alibaba
BABA
$269B
| $4.98M | 0.1% |
+47,920
| New | +$4.92M |
|
230
Dollar Tree
DLTR
$23.1B
| $4.97M | 0.1% |
+70,679
| New | +$4.46M |
|
231
Delta Air Lines
DAL
$55.9B
| $4.93M | 0.1% |
+100,217
| New | +$4.22M |
|
|
ACOR
232
DELISTED
Acorda Therapeutics
ACOR
| $4.9M | 0.1% |
+1,000
| New | +$4.29M |
|
233
Lumen
LUMN
$6.53B
| $4.87M | 0.1% |
+123,058
| New | +$4.92M |
|
|
CRC
234
DELISTED
California Resources Corporation
CRC
| $4.82M | 0.1% |
+87,511
| New | +$5.27M |
|
|
AUY
235
DELISTED
Yamana Gold, Inc.
AUY
| $4.81M | 0.1% |
+1,188,851
| New | +$5.38M |
|
|
DRC
236
DELISTED
DRESSER-RAND GROUP INC
DRC
| $4.79M | 0.1% |
+58,500
| New | +$4.76M |
|
237
Nektar Therapeutics
NKTR
$2.39B
| $4.73M | 0.1% |
+20,333
| New | +$4.35M |
|
|
DFS
238
DELISTED
Discover Financial Services
DFS
| $4.72M | 0.1% |
+72,058
| New | +$4.62M |
|
239
Neurocrine Biosciences
NBIX
$17.7B
| $4.69M | 0.1% |
+210,000
| New | +$3.98M |
|
|
BLUE
240
DELISTED
bluebird bio
BLUE
| $4.68M | 0.1% |
+3,937
| New | +$2.63M |
|
241
PTC
PTC
$13.7B
| $4.67M | 0.1% |
+127,500
| New | +$4.72M |
|
242
Vanguard Large-Cap ETF
VV
$51.9B
| $4.61M | 0.1% |
+48,990
| New | +$4.52M |
|
243
Toronto Dominion Bank
TD
$198B
| $4.6M | 0.1% |
+95,893
| New | +$4.63M |
|
244
Bio-Rad Laboratories Class A
BIO
$8.42B
| $4.58M | 0.1% |
+38,000
| New | +$4.37M |
|
245
Goldman Sachs
GS
$313B
| $4.56M | 0.1% |
+23,531
| New | +$4.42M |
|
246
TC Energy
TRP
$73.5B
| $4.51M | 0.09% |
+91,519
| New | +$4.44M |
|
247
Warner Bros
WBD
$64.6B
| $4.47M | 0.09% |
+129,757
| New | +$4.5M |
|
248
Valero Energy
VLO
$89.8B
| $4.43M | 0.09% |
+89,556
| New | +$4.34M |
|
249
Williams Companies
WMB
$90.5B
| $4.42M | 0.09% |
+98,394
| New | +$5.03M |
|
250
Thermo Fisher Scientific
TMO
$211B
| $4.41M | 0.09% |
+35,168
| New | +$4.28M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for Candriam SCA, which disclosed 616 positions worth $4.78B. Its ten largest holdings account for 14% of the portfolio.
Its largest position is Gilead Sciences: 888,125 shares worth $83.7M.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, followed by Financials and Technology.
- Candriam SCA's largest Q4 2014 buy was Gilead Sciences: 888,125 shares worth $83.7M.
- Candriam SCA's ten largest holdings make up 14% of its $4.78B portfolio in Q4 2014.
- Candriam SCA disclosed 616 positions in Q4 2014, its first 13F filing on record.
Based on Candriam SCA's 13F filing for Q4 2014, filed 26 Mar 2015.